7-OH vs Kratom vs MIT: What Is the Difference?

One of the most important kratom questions in 2026 is also one of the most misunderstood: what is the difference between botanical kratom, MIT products, and 7-OH?

The difference is pharmacological, not just terminological

Kratom leaf, MIT products, and concentrated 7-OH are all consumed for psychoactive effects, but they do not create the same exposure. Mitragynine and 7-OH both act at mu-opioid receptors, with 7-OH producing substantially stronger receptor activation.

Ordinary leaf contains a complex alkaloid mixture with mitragynine as the principal alkaloid and only low natural levels of 7-OH. MIT extracts concentrate mitragynine. Many modern 7-OH tablets, gummies, and shots instead center the product on enriched or semi-synthetic 7-OH, creating exposure that is pharmacologically distinct from chewing leaf or swallowing leaf powder.

Unwanted effects and dependence can occur across these categories. Concentrated 7-OH deserves separate concern because some consumers develop rapidly increasing tolerance and difficult withdrawal. MIT is active, but it is not an effect-equivalent name for 7-OH.

The short version

Botanical kratom refers to products built around the kratom leaf itself. That usually means powdered leaf, capsule products filled with leaf powder, and traditional strain-family names such as red, green, white, yellow, Bali, Borneo, Thai, Malay, and Maeng Da. These names help customers shop the category, but the center of the product is the plant material.

MIT is short for mitragynine, the main alkaloid customers see discussed in modern kratom product labeling. A product that uses MIT language should make the format, strength, flavor, and count or size clear. MIT products are not the same thing as ordinary powder, and they should not be buried inside vague product names. Clear labeling is what lets customers understand the product family before they compare options.

7-OH is short for 7-hydroxymitragynine. Natural kratom leaf can contain trace amounts of 7-OH, but the modern policy fight is about products where 7-OH is isolated, enhanced, synthesized, or pushed far beyond ordinary leaf chemistry. That is the category federal agencies and many responsible kratom voices are trying to separate from botanical kratom and clearly labeled MIT products.

Why the distinction matters now

For years, many websites treated kratom as one giant bucket. That is no longer enough. A pouch of leaf powder, a bottle of capsules, an MIT chewable tablet, and a synthetic 7-OH product do not raise the same shopping, labeling, and legal questions. When all of those things are blurred together, customers get confused and regulators get a cleaner excuse to treat the entire category as suspicious.

The better model is simple: name the category accurately. Botanical powder should look and read like botanical powder. Capsules should say capsule count and fill. MIT products should state the labeled MIT option and flavor or size. Synthetic or elevated 7-OH should not borrow the credibility of kratom leaf. A mature marketplace needs sharper language than the old catch-all kratom descriptions that blurred every format together.

How to shop the categories

If you are comparing ordinary kratom products, start with the format: powder or capsules. Powder is loose and flexible. Capsules are pre-filled and cleaner to handle. Bulk capsules are a separate shopping lane for larger quantity needs.

If you are comparing MIT products, start with the labeled MIT direction, flavor, and count or size. Kratom Paradise separates MIT chewable tablets, MIT extract powder, and bulk MIT options so customers do not have to decode a cluttered catalog.

If a product leads with 7-OH, extreme potency language, novelty packaging, or a format that feels disconnected from botanical kratom, treat it as a different category. The label should not force you to guess whether you are looking at leaf, MIT, or synthetic/elevated 7-OH.

What the 2026 federal action changed

The federal record now has two separate lanes. DEA's August 26, 2026 temporary order placed mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I. The proposed federal threshold for 7-OH remains a separate process, with HHS accepting threshold comments through September 10, 2026. Neither lane should be summarized as a blanket rule for every product described as kratom or MIT.

Kratom Paradise supports that separation. The goal is not to make the category boring. The goal is to keep it honest: botanical kratom in its lane, MIT products labeled clearly, and synthetic 7-OH kept out of the Kratom Paradise catalog.

DEA temporary order for mitragynine pseudoindoxyl, MGM-15, and MGM-16. HHS extension for comments on the proposed 7-OH threshold. FDA 7-OH overview.

A practical three-term glossary

Botanical kratom begins with Mitragyna speciosa leaf and commonly appears as powder or leaf-filled capsules. Familiar regional and color-family names help distinguish products within that botanical category.

MIT is shorthand for mitragynine. MIT-labeled products use strength, format, flavor, count, or size to identify the exact option being offered.

7-OH is shorthand for 7-hydroxymitragynine. Trace botanical occurrence should not be confused with products centered on isolated, enhanced, synthetic, or unusually elevated 7-OH.

August 2026 federal status: two separate lanes

DEA's August 26 temporary order placed mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I. It did not place mitragynine itself in Schedule I and did not make the separate proposed threshold for 7-OH effective.

HHS extended comments on the proposed 7-OH threshold through September 10, 2026. A product name alone does not decide how federal, state, or local rules apply; the actual compound, concentration, processing, package, place, and date still matter. The federal status tracker keeps the two processes separate.

The identified finished-tablet report for pressed Mitragynine Tablet lot M/150/002 lists 146 mg mitragynine, 0.148 mg 7-hydroxymitragynine, and 153 mg total Mitragyna alkaloids per unit. Open the complete finished-tablet COA. The report does not identify Mango flavor and is not a legal certification or equivalency claim.